260 related articles for article (PubMed ID: 25460144)
21. Tumor targeting by pH-sensitive, biodegradable, cross-linked N-(2-hydroxypropyl) methacrylamide copolymer micelles.
Zhou Z; Li L; Yang Y; Xu X; Huang Y
Biomaterials; 2014 Aug; 35(24):6622-35. PubMed ID: 24814427
[TBL] [Abstract][Full Text] [Related]
22. Synergistic enhancement of anticancer therapeutic efficacy of HPMA copolymer doxorubicin conjugates via combination of ligand modification and stimuli-response srategies.
Li L; Zhou M; Huang Y
Int J Pharm; 2018 Jan; 536(1):450-458. PubMed ID: 29237570
[TBL] [Abstract][Full Text] [Related]
23. RGD-modified PEG-PAMAM-DOX conjugates: in vitro and in vivo studies for glioma.
Zhang L; Zhu S; Qian L; Pei Y; Qiu Y; Jiang Y
Eur J Pharm Biopharm; 2011 Oct; 79(2):232-40. PubMed ID: 21496485
[TBL] [Abstract][Full Text] [Related]
24. Bloodstream Stability Predetermines the Antitumor Efficacy of Micellar Polymer-Doxorubicin Drug Conjugates with pH-Triggered Drug Release.
Chytil P; Šírová M; Kudláčová J; Říhová B; Ulbrich K; Etrych T
Mol Pharm; 2018 Sep; 15(9):3654-3663. PubMed ID: 29543465
[TBL] [Abstract][Full Text] [Related]
25. Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification.
Chytil P; Etrych T; Konák C; Sírová M; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2006 Sep; 115(1):26-36. PubMed ID: 16899320
[TBL] [Abstract][Full Text] [Related]
26. Dual fluorescent HPMA copolymers for passive tumor targeting with pH-sensitive drug release: synthesis and characterization of distribution and tumor accumulation in mice by noninvasive multispectral optical imaging.
Hoffmann S; Vystrčilová L; Ulbrich K; Etrych T; Caysa H; Mueller T; Mäder K
Biomacromolecules; 2012 Mar; 13(3):652-63. PubMed ID: 22263698
[TBL] [Abstract][Full Text] [Related]
27. Doxorubicin-loaded, charge reversible, folate modified HPMA copolymer conjugates for active cancer cell targeting.
Li L; Yang Q; Zhou Z; Zhong J; Huang Y
Biomaterials; 2014 Jun; 35(19):5171-87. PubMed ID: 24702960
[TBL] [Abstract][Full Text] [Related]
28. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
Etrych T; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
[TBL] [Abstract][Full Text] [Related]
29. HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity.
Etrych T; Strohalm J; Kovár L; Kabesová M; Ríhová B; Ulbrich K
J Control Release; 2009 Nov; 140(1):18-26. PubMed ID: 19632282
[TBL] [Abstract][Full Text] [Related]
30. Influence of coupling bonds on the anti-tumor activity of polymer-pirarubicin conjugates.
Mo G; Hu X; Liu S; Yue J; Wang R; Huang Y; Jing X
Eur J Pharm Sci; 2012 Aug; 46(5):329-35. PubMed ID: 22426082
[TBL] [Abstract][Full Text] [Related]
31. HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity.
Ulbrich K; Etrych T; Chytil P; Jelínková M; Ríhová B
J Control Release; 2003 Feb; 87(1-3):33-47. PubMed ID: 12618021
[TBL] [Abstract][Full Text] [Related]
32. HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release.
Etrych T; Sírová M; Starovoytova L; Ríhová B; Ulbrich K
Mol Pharm; 2010 Aug; 7(4):1015-26. PubMed ID: 20518512
[TBL] [Abstract][Full Text] [Related]
33. Highly effective anti-tumor nanomedicines based on HPMA copolymer conjugates with pirarubicin prepared by controlled RAFT polymerization.
Randárová E; Nakamura H; Islam R; Studenovský M; Mamoru H; Fang J; Chytil P; Etrych T
Acta Biomater; 2020 Apr; 106():256-266. PubMed ID: 32058082
[TBL] [Abstract][Full Text] [Related]
34. Copoly(styrene-maleic acid)-pirarubicin micelles: high tumor-targeting efficiency with little toxicity.
Greish K; Nagamitsu A; Fang J; Maeda H
Bioconjug Chem; 2005; 16(1):230-6. PubMed ID: 15656596
[TBL] [Abstract][Full Text] [Related]
35. Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours.
Etrych T; Subr V; Laga R; Ríhová B; Ulbrich K
Eur J Pharm Sci; 2014 Jul; 58():1-12. PubMed ID: 24632485
[TBL] [Abstract][Full Text] [Related]
36. Overcoming multidrug resistance in Dox-resistant neuroblastoma cell lines via treatment with HPMA copolymer conjugates containing anthracyclines and P-gp inhibitors.
Koziolová E; Janoušková O; Cuchalová L; Hvězdová Z; Hraběta J; Eckschlager T; Sivák L; Ulbrich K; Etrych T; Šubr V
J Control Release; 2016 Jul; 233():136-46. PubMed ID: 27189135
[TBL] [Abstract][Full Text] [Related]
37. Antitumor activity of N-(2-hydroxypropyl) methacrylamide copolymer-Mesochlorine e6 and adriamycin conjugates in combination treatments.
Shiah JG; Sun Y; Peterson CM; Straight RC; Kopecek J
Clin Cancer Res; 2000 Mar; 6(3):1008-15. PubMed ID: 10741728
[TBL] [Abstract][Full Text] [Related]
38. Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates.
Lidický O; Janoušková O; Strohalm J; Alam M; Klener P; Etrych T
Molecules; 2015 Nov; 20(11):19849-64. PubMed ID: 26556320
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of primary and metastatic tumors in mice by E-selectin-targeted polymer-drug conjugates.
Shamay Y; Raviv L; Golan M; Voronov E; Apte RN; David A
J Control Release; 2015 Nov; 217():102-12. PubMed ID: 26297207
[TBL] [Abstract][Full Text] [Related]
40. The comparison of in vivo properties of water-soluble HPMA-based polymer conjugates with doxorubicin prepared by controlled RAFT or free radical polymerization.
Chytil P; Šírová M; Koziolová E; Ulbrich K; Říhová B; Etrych T
Physiol Res; 2015; 64(Suppl 1):S41-9. PubMed ID: 26447594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
